ProCyte Corporation Merger with PhotoMedex Approved.

REDMOND, Wash. -- ProCyte Corporation (OTCBB:PRCY) and PhotoMedex, Inc. (NASDAQ:PHMD) announced today that both companies have shareholder approval to complete their merger in a stock-for-stock transaction. The merger is expected to close later today or early next week.

At a reconvened special meeting of shareholders held this morning, ProCyte shareholders voted to approve the merger agreement and the merger between the two companies. Approximately 11,121,900 shares, representing over 70% of ProCyte's 15,822,516 shares of common stock outstanding, voted in favor of the merger. Under Washington law, the affirmative vote of two-thirds of the outstanding shares of ProCyte common stock was needed to complete the merger.

Previously, on March 3, 2005, at a special meeting of the PhotoMedex stockholders, the merger agreement and merger were approved including the issuance of PhotoMedex shares as consideration for ProCyte shares.

Under the terms of the agreement, PhotoMedex will issue 0.6622 shares of its common stock in exchange for each outstanding share of ProCyte common stock. PhotoMedex expects to issue approximately 10.5 million shares of common stock. The combined company will operate under the name PhotoMedex, Inc. and will trade on the NASDAQ National Market under the ticker "PHMD." The combined company will be headquartered in Montgomeryville, PA and will have operations in Carlsbad, California and Redmond, Washington.

Jack Clifford, President and CEO of ProCyte Corporation, commented, "We are pleased to have received the support of our shareholders in approving this merger. We can now begin the important work of integrating our two companies. We look forward to operating as a combined company, which we believe will continue to gain momentum in providing dermatology and surgical products and services."

About ProCyte

ProCyte Corporation develops and markets products based on its patented, clinically proven GHK and AHK Copper Peptide technology for skin health, hair care and wound care. The Company sells directly to dermatologists, plastic and cosmetic surgeons, spas and salons and through licenses with strategic partners into the consumer market, including its long-term worldwide license agreement with Neutrogena(R), a Johnson & Johnson company (NYSE:JNJ). ProCyte brands include Neova(R), VitalCopper(R), NextDerm(TM), Simple Solutions(R) and AquaSante(R) Skin Care products; Complex Cu3(R), GraftCyte(R) and Tricomin(R). Additional information is available by visiting the Company's website at www.procyte.com.

About PhotoMedex

PhotoMedex provides contract medical procedures to hospitals, surgi-centers and doctors' offices, offering a wide range of products and services across multiple specialty areas, including dermatology, urology, gynecology, orthopedics, and other surgical specialties. The company is a leader in the development, manufacturing and marketing of medical laser products and services.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on managements' current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The forward-looking statements contained in this release include statements about future financial and operating results of ProCyte Corporation ("ProCyte") and PhotoMedex, Inc. ("PhotoMedex") and the pending acquisition of ProCyte by PhotoMedex.

The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the risk that ProCyte's business will not be integrated successfully with that of PhotoMedex, costs related to the merger, risks relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on strategic partners, ability to obtain financing, competitive products and other risks identified in PhotoMedex's and ProCyte's respective filings with the SEC, including the joint proxy statement/prospectus dated January 21, 2005. PhotoMedex and Procyte are under no obligation to (and expressly disclaim any such obligation to) update or alter these forward-looking statements, whether as a result of new information, future events or otherwise.